Vasopharm raises EUR 20m to fund Phase III study of VAS203
21 January 2016 | By Victoria White
Vasopharm has designed a Phase III registration study in Europe of VAS203 in in moderate to severe traumatic brain injury...
List view / Grid view
News
Pharma calls for collective action to combat antimicrobial resistance
21 January 2016 | By Victoria White
More than 80 companies and organisations have signed the Declaration on Combating Antimicrobial Resistance (AMR), an industry-wide call to action...
Sartorius Stedim Biotech presents new crossflow filtration system for process development
21 January 2016 | By Sartorius Stedim Biotech
The ideal solution for scaling studies and low volume ultra- and diafiltration operations...
FDA grants breakthrough therapy designation to venetoclax combo in CLL
20 January 2016 | By Victoria White
Venetoclax is an investigational small molecule designed to selectively bind and inhibit the BCL-2 protein, which plays an important role in a process called apoptosis...
Gavi funds Merck’s development of Ebola vaccine
20 January 2016 | By Victoria White
Gavi has provided US$ 5 million towards the development of Merck’s rVSV∆G-ZEBOV-GP live attenuated Ebola Zaire vaccine, on the understanding that it will be submitted for licensure by the end of 2017...
Hepatitis B therapeutics market to rise to $3b by 2024, says GlobalData
20 January 2016 | By Victoria White
GlobalData says the expansion will be slight due to the patent expiration of all existing branded drugs in the chronic hepatitis B therapeutics space during the forecast period, and continued low diagnosis and treatment rates of the disease...
Shire bets big on rare diseases
20 January 2016 | By Black Swan Analysis
Speciality pharma firm Shire has agreed to buy Baxalta for around $32 billion (£22 billion), to further expand its portfolio of treatments for rare diseases...
Trial of IMCgp100, durvalumab and tremelimumab in melanoma starts
20 January 2016 | By Victoria White
Immunocore has announced the start of the Phase Ib/II combination trial evaluating IMCgp100 with durvalumab and tremelimumab for the treatment of metastatic cutaneous melanoma...
Lilly and Incyte submit NDA for baricitinib to the FDA
Lilly and Incyte have announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis (RA).
Marketing Authorisation granted for Oncaspar as combination therapy in ALL
19 January 2016 | By Victoria White
With this authorisation, Oncaspar will provide an important treatment option for more European patients with this rapidly progressing cancer of the white blood cells...
Acorda to acquire Biotie; gains rights to tozadenant
19 January 2016 | By Victoria White
In acquiring Biotie for approximately $363 million, Acorda will obtain worldwide rights to tozadenant, an oral adenosine A2a receptor antagonist currently in Phase 3 development in Parkinson’s disease...
Hodgkin’s lymphoma treatment market to hit $1.4b by 2024, says GlobalData
19 January 2016 | By Victoria White
GlobalData says the impressive growth in the market will be attributable to label extensions for Seattle Genetics’ Adcetris and the launch of new therapies for relapse or refractory Hodgkin’s lymphoma...
Aridhia’s data platform selected by EPAD for dementia prevention project
19 January 2016 | By Victoria White
The EPAD project is a powerful research collaboration between European organisations in the public and private sectors which focuses on prevention of dementia in the early stages of the disease...
Sir Ranulph Fiennes visits Source BioScience to celebrate the launch of the world’s first -70°C walk-in chamber
With temperatures regularly reaching -70°C, the coldest place on earth is unsurprisingly the Antarctic. Source BioScience is now able to replicate these bone-chilling temperatures in an innovative, efficient storage solution.
Eisai’s lenvatinib receives FDA priority review
18 January 2016 | By Victoria White
The FDA has accepted for Priority Review Eisai’s supplemental New Drug Application for lenvatinib for the potential treatment of patients with renal cell carcinoma...
